Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

Lilly, Boehringer Collaborate on Diabetes Drugs(2)

By Pharmaceutical Processing | January 11, 2011

INDIANAPOLIS (AP) — Eli Lilly will pay Boehringer Ingelheim $387.4 million
and collaborate with the German drugmaker to develop diabetes drugs with the
U.S. pharmaceutical company facing the expiration of some
of its key patents.

Lilly, based in Indianapolis, loses patent protection this year for its
top-selling drug, the anti-psychotic Zyprexa, and faces the loss of some other
key patents in the next few years. The drugmaker said Tuesday that the deal with
Boehringer Ingelheim offers the potential of boosting near-term revenue.

Lilly could receive more than $1 billion in future payments depending on how
well the collaboration performs and whether the drugs under development reach
certain sales milestones. Boehringer Ingelheim will be eligible for future
payments totaling about $807 million.

The collaboration includes two Lilly insulins expected to enter late-stage
testing this year and a type 2 diabetes treatment from Boehringer Ingelheim that
is being reviewed by regulators.

Shares of Eli Lilly and Co. rose slightly in premarket trading. 

Related Articles Read More >

This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
sherwin-williams-pharma-facility (1)
Sherwin-Williams expands flooring solutions for pharma facilities
PHARMAP 2025: Pharma leaders converge in Berlin for fifth anniversary summit
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE